Arsenic for low-risk MDS
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests an oral form of arsenic in people with low-risk myelodysplastic syndromes (MDS) who need regular red blood cell transfusions and haven't gotten enough benefit from standard treatments. It aims to see if this drug can help reduce transfusion needs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with low-risk MDS (very low, low, or intermediate risk).
- You need regular red blood cell transfusions (at least 3 transfusions in 16 weeks).
- You have tried or are not eligible for standard treatments like erythropoiesis-stimulating agents (ESA drugs), luspatercept, or lenalidomide.
- You are 18 years or older.
- You have adequate kidney and liver function, and no major heart problems.
- You have not had any active cancer (other than some skin cancers) in the last year.
- If you could become pregnant, you agree to use effective birth control and have regular pregnancy tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests R289 in adults with lower-risk myelodysplastic syndromes (MDS) whose disease keeps causing anemia and/or ongoing need for red blood cell transfusions. It may help reduce blood problems and treat MDS when standard options haven’t worked well enough or aren’t suitable.
This study looks at how well transfusions work and how they affect quality of life in people with lower-risk MDS who need regular blood transfusions. The goal is to find what predicts a good transfusion response and to improve care.
This trial tests whether adding arsenic trioxide (a drug) to the standard transplant process can lower the risk of leukemia coming back. It is for people with AML or MDS who have a certain genetic change (TP53 mutation) and are about to have their first stem cell transplant from a matched donor.
This trial tests an investigational drug called elritercept for adults with a specific type of low-risk MDS (myelodysplastic syndromes) who have anemia (low red blood cells) and need regular blood transfusions. The goal is to see if elritercept can reduce or eliminate the need for transfusions.
This trial tests three different treatments for people with a type of bone marrow disorder called low-risk myelodysplastic syndrome (MDS) that causes low red blood cells (anemia). The goal is to see which treatment works best and to find out more about the disease.
This study tests a new drug, momelotinib, for people with a low-risk form of myelodysplastic syndrome (MDS) who need red blood cell transfusions and have already tried one other treatment (like ESAs or luspatercept). The goal is to see if momelotinib can help reduce transfusion needs.
Hear when a new Low Risk Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.